Bajas Tasas de Progresión Radiográfica Asociadas con Eficacia Clínica Siguiendo hasta 2 Años de Tratamiento con Guselkumab: Resultados de un Ensayo Clínico Aleatorizado de Fase 3, Doble Ciego, Controlado con Placebo con Pacientes Naïve de Biológicos con Artritis Psoriasica Activa
RMD Open. 2023 doi: 10.1136/rmdopen-2022-002789
Data from this paper provides a robust analysis of radiographic progression through 2 years in a phase 3 study of guselkumab in patients with PsA. This study sought to evaluate the relationship between radiographic progression and clinical outcomes in post hoc analyses of patients with PsA receiving up to 2 years of guselkumab therapy in DISCOVER-2.
Data also highlight the importance of addressing structural damage in a timely manner to optimise long-term patient outcomes, including preservation of function.
Keywords:
